Drug profile

The FDA adverse-event record for Florfenicol, Terbinafine Hcl, Mometasone Furoate

112 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Florfenicol, Terbinafine Hcl, Mometasone Furoate. See the species affected, top reactions, and outcomes below.

112
adverse-event reports
7.1%
death-coded share
Dog
most-reported species
23
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
112
Total Reports
8
Deaths Reported
7.1%
Death Rate

Active Ingredients

Florfenicol, Terbinafine Hcl, Mometasone Furoate

Administration Routes

Auricular (Otic)UnknownTopicalOphthalmic

Species Affected

Dog 101
Cat 11

Most Affected Breeds

Retriever - Labrador 14
Shih Tzu 9
Terrier - Yorkshire 8
Retriever - Golden 6
Domestic Shorthair 6
Terrier - Bull - American Pit 5
Terrier (unspecified) 5
Poodle - Miniature 5
Dog (unknown) 3
Shepherd Dog - Australian 3

Most Reported Reactions

Vomiting 23
Ataxia 22
Not eating 17
Ocular discharge 16
Behavioural disorder NOS 15
Vestibular disorder NOS 14
Head tilt - ear disorder 13
Corneal ulcer 12
Head shake - ear disorder 12
Lack of efficacy - NOS 12
Diarrhoea 11
Lethargy (see also Central nervous system depression in Neurological) 11

Outcome Breakdown

Ongoing
61 (54.5%)
Outcome Unknown
29 (25.9%)
Recovered/Normal
11 (9.8%)
Euthanized
4 (3.6%)
Died
4 (3.6%)
Recovered with Sequela
3 (2.7%)

Florfenicol, Terbinafine Hcl, Mometasone Furoate Adverse Event Insights

112 reports name Florfenicol, Terbinafine Hcl, Mometasone Furoate; 8 recorded a death outcome (7.1% of reported events, not a population-level mortality rate). Active ingredient: Florfenicol, Terbinafine Hcl, Mometasone Furoate. Administration routes: Auricular (Otic), Unknown, Topical, Ophthalmic.

By species: Dog (101 reports), Cat (11 reports). By breed: Retriever - Labrador (14), Shih Tzu (9), Terrier - Yorkshire (8).

Leading clinical signs: Vomiting (23), Ataxia (22), Not eating (17), Ocular discharge (16). Outcome, 112 coded reports: Ongoing leads at 54.5%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.